



Schedule 4 – Information on Management Positions

Jørgen Bardenfleth

Deputy Chairman of the Board, Scandion Oncology A/S, and member of the Board of Directors since 2018.

Education: MSc in Engineering from the Technical University of Denmark (DTU) and an MBA from the University of California, Los Angeles.

Background: Professional board member since 2013, prior General Manager in high tech companies Microsoft, Intel and Hewlett-Packard 1989-2013. Board and steering committee work in Danish Science Parks, Innovation Fund Denmark and Innovation Technology consortias.

Other ongoing assignments: Chairman of the Board in Lyngsoe Systems, Impero, Dubex and Symbion. Vice Chairman in BLOXHUB. Boardmember in Bizbrains, CN3, Accelerace and Valloe Stift.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Thomas Feldthus

Member of the Board of Directors in Scandion Oncology A/S since 2018.

Education: MSc in Engineering from the Technical University of Denmark (DTU), MSc in Management and Economics from the University of London, and a Fellow of the London Business School Sloan Program.

Background: Previously, vVD, CFO and co-founder of Saniona and also CFO and co-founder of Symphogen A/S.

Other ongoing assignments: Chairman of Rehler ApS, Board member Synklino A/S and ResoTher Pharma ApS.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Martin Møller

Member of the Board of Directors in Scandion Oncology A/S since 2021.

Education: MA in comparative literature from the University of Copenhagen.

Background: Worked for more than 20 years in McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.

Other ongoing assignments: Board member in Immunovia AB and Rehler ApS.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Bo Rode Hansen

President & CEO and member of the Board of Directors in Scandion Oncology A/S since 2020.

Education: MSc, Ph.D., MBA.

Background: Previously, President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris (*acquired by Roche*).

Other ongoing assignments: Advisor for Novo Seeds.

Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.



Keld Flintholm Jørgensen

Proposed Member of the Board of Directors in Scandion Oncology A/S from April 2022.

Education: BSc in Economics & Business Administration and MSc in Business Economics & Auditing, Copenhagen Business School.

Background: +20 years of experience within the global pharma industry across different functional areas such as Business Development, Corporate Strategy, Finance and Auditing. Served in several finance leadership positions at Roche from 2000 and until 2011, where Keld joined Roche Strategic Partnering. From 2017 he was promoted to Global Head of Roche Strategic Partnering and a member of the Roche Pharma's Late Stage Portfolio Committee. In 2019, Keld joined Lundbeck as EVP and Chief Business Officer, responsible for Corporate Strategy and Business Development. During the past +10 years in BD, Keld has executed M&A's and partnering deals worth >10 bio USD.

Other ongoing assignments: EVP & Chief Business Officer of Lundbeck A/S.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Alejandra Mørk

Proposed Member of the Board of Directors in Scandion Oncology A/S from April 2022.

Education: PhD and MSc Pharm.

Background: Worked all her carrier in drug development. First in Nycomed Pharma for 18 years in various leadership positions in Project Management, Clinical Development, Regulatory Affairs and as overall responsible for Drug Development being part of Nycomed top-management. In 2008 Alejandra acquired KLIFO A/S to build an international drug development consultancy supporting biotech and pharma companies to progress and increase value of their product development projects. Alejandra Mørk has since 2011 been member of the Board of Danish Biotech.

Other ongoing assignments: Board member in Danish Biotech and Cyxone AB. CEO of KLIFO A/S and member of the Danish Academy of Technical Sciences.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Martine J. van Vugt

Proposed Member of the Board of Directors in Scandion Oncology A/S from April 2022.

Education: PhD.

Background: +20 years of biotechnology industry experience and is a proven leader with a successful track record of leading high-performing, global cross-functional teams in a networked biotech environment. Martine is skilled in developing joint business value propositions, designing partnership structures and management of alliances. Martine is an expert in corporate transactional and licensing operations, including strategic partnering, in- and out-licensing as well as asset divestment and purchases. Martine is recognized internally and in industry for her strong leadership, communication and negotiation skills, and effectively blends analytical skills with a natural leadership style grounded in integrity and science. Martine is an inventor of Darzalex® and Tepezza.

Other ongoing assignments: Senior Vice President, Corporate Strategy and Planning at Genmab. Board member in Immagine B.V., NOXXON Pharma N.V and HollandBIO.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.